Innovative Vaccine Platform Baseimmune leverages advanced AI and deep learning to predict pathogen mutations, positioning them as a pioneer in next-generation vaccine development. This innovative approach opens opportunities to collaborate with biotech firms and healthcare providers seeking cutting-edge immunotherapy solutions.

Rapid Funding Growth The company recently secured over 11 million USD in Series A funding from high-profile investors like MSD Global Health Innovation Fund and IQ Capital, demonstrating strong investor confidence and potential for strategic partnerships in global health markets.

Strategic Collaborations Partnerships with the London BioScience Innovation Centre provide a collaborative environment for expansion and development, creating sales opportunities through joint research initiatives and co-developments in biotech innovation.

Market Expansion Potential With a focus on future pathogens and immunotherapy strategies, Baseimmune is well-positioned to target government agencies, pharmaceutical companies, and healthcare organizations aiming to enhance vaccine preparedness and pandemic response capabilities.

Small but Growing As a compact team of up to 50 employees, Baseimmune presents an agile partner for customized solutions, making it attractive to clients seeking innovative, adaptable, and personalized biotech services in a competitive landscape.